• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Is Daily Cannabis Use Linked to Depression and Suicidal Behaviors?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The use of cannabis and suicide rates among US adults have both increased over the past decade, but whether an association exists between the two is not well understood
  • Han et al. (JAMA Network Open, 2021) assessed whether cannabis use and cannabis use disorder (CUD) are associated with a higher prevalence of suicidality among young adults

METHODS:

  • Survey study
  • Population
    • US adults aged 18 to 34 years who participated in the National Surveys on Drug Use and Health, between 2008 and 2019
  • Exposures
    • Prevalence of past-year daily or near daily cannabis use (≥300 days in the past year)
    • CUD | Based on DSM-IV diagnostic criteria
    • Major depressive episode (MDE) | Based on DSM-IV diagnostic criteria
  • Primary outcome
    • Past year suicidal ideation, plan, and attempt

RESULTS:

  • 281,650 adults
  • In all examined sociodemographic subgroups, over the past decade, there was an increase in
    • Past-year suicidal ideation and plan
    • Daily cannabis use (except among current high-school students)
    • Past-year suicide attempt
  • After controlling for MDE, CUD, cannabis use status, and potential confounding factors, the adjusted prevalence of suicidal ideation, plan, and attempt increased 1.4 to 1.6 times from the 2008-2009 to 2018-2019 periods
    • Suicidal ideation: Adjusted risk ratio (aRR) 1.4 (95% CI, 1.3 to 1.5)
    • Suicide plan: aRR 1.6 (95% CI, 1.5 to 1.9)
    • Suicide attempt: aRR 1.4 (95% CI, 1.2 to 1.7)
  • Past-year CUD, daily cannabis use, and nondaily cannabis use were associated with a higher prevalence of past-year suicidal ideation, plan, and attempt in both sexes (P<0.001)
    • Suicidal ideation among women without MDE
      • With CUD: 13.9%
      • Without CUD: 3.5%
    • Suicidal ideation among men without MDE
      • With CUD: 9.9%
      • Without CUD: 3.0%
  • Past-year CUD, daily cannabis use, and nondaily cannabis use were more often associated with suicidal behavior in women
    • Suicide plan among those with MDE (P<0.001)
      • Women with CUD: 23.7%
      • Men with CUD: 15.6%

CONCLUSION:

  • Between 2008 and 2019, suicidal behaviors in US young adults increased, both among cannabis daily-users and those with CUD, but also among non-users
    • There are likely other factors influencing the upward suicidality trend
  • Cannabis use and depression may be associated with suicidal behavior
  • Limitations include
    • Suicidal behavior may be underreported for multiple reasons including self-reporting
    • Data on anxiety and impulse-control disorders were not available
  • The authors state

The results of this survey study indicate that CUD, daily cannabis use, and even nondaily cannabis use are associated with the risks of suicidal ideation, plan, and attempt in both young adult men and women, but significantly more so in women than men

Learn More – Primary Sources:

Associations of Suicidality Trends With Cannabis Use as a Function of Sex and Depression Status

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ABCD Study Results: Is There a Link Between Prenatal Cannabis Use and Adverse Psychopathological Effects in Children?
Does Cannabis Use During Pregnancy Increase Risk of Preterm Birth?
Is Progestin-Based Contraception Linked to Depression?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site